Abstracts tagged "spondyloarthritis"

Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Casper Webers¹, Augusta Ortolan², Alexandre Sepriano³, Louise Falzon⁴, Xenofon Baraliakos⁵, Robert Landewé⁶, Sofia Ramiro⁷, Désirée van der Heijde⁸ and Elena Nikiphorou⁹, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²University of Padova/Leiden University Medical Center, Padova, Italy, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁹Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…
Abstract Number: 0853 • ACR Convergence 2022
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
Walter P Maksymowych¹, Nisha Varma², Arthur Meyers³, Jennifer Stimec⁴, Nikolay Tzaribachev⁵, Jonathan Akikusa⁶, Tarimobo Otobo⁴, Marion von Rossum⁷, Andrea Doria⁴ and Nele Herregods⁸, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Paediatric Radiology, The Royal Children's Hospital Melbourne, Melbourne, Australia, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, ON, Canada, ⁵PRI Research Institute, Bad Bramstedt, Germany, ⁶Rheumatology Service, Royal Children’s Hospital, Melbourne, Melbourne, Australia, ⁷Emma Children’s Hospital, Dept Pediatrics, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Ghent University Hospital, Ghent, Belgium
Background/Purpose: The evaluation of the sacroiliac joints (SIJ) in children with Juvenile Idiopathic Arthritis (JIA) increasingly relies on the use of MRI since radiography is…
Abstract Number: 1043 • ACR Convergence 2022
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Jan Brandt-Juergens¹, Martin Rudwaleit², Frank Behrens³, Christopher Ritchlin⁴, Daniel Peterlik⁵, Erhard Quebe-Fehling⁶, Renato Calheiros⁷ and Atul Deodhar⁸, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corp., Hoboken, NJ, ⁸Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…
Abstract Number: 1258 • ACR Convergence 2022
Development of International Consensus on a Standardized Image Acquisition Protocol for Diagnostic Evaluation of the Sacroiliac Joints by MRI – an ASAS-SPARTAN Collaboration
Robert G Lambert¹, Xenofon Baraliakos², Stephanie Bernard³, John Carrino⁴, Torsten Diekhoff⁵, Iris Eshed⁶, Kay-Geert Hermann⁷, Nele Herregods⁸, Jacob Jaremko¹, Lennart Jans⁸, Anne Jurik⁹, John O'Neill¹⁰, Monique Reijnierse¹¹, Michael Tuite¹² and Walter P Maksymowych¹³, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Brooke Army Medical Center, Fort Sam Houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sheba Medical Center, Tel Aviv, Israel, ⁷Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Aarhus University Hospital, Aarhus, Denmark, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹³Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In 2009, ASAS published a 'Definition of active sacroiliitis on MRI for classification of axial spondyloarthritis (axSpA)'. This definition relied on two MRI sequences…
Abstract Number: 1599 • ACR Convergence 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Joseph Merola¹, Robert Landewé², Iain B McInnes³, Philip J Mease⁴, Christopher Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Richard Warren¹¹, Barbara Ink¹², Deepak Assudani¹², Rajan Bajracharya¹², Jason Coarse¹³ and Laura Coates¹⁴, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Sorbonne Université, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…
Abstract Number: 2196 • ACR Convergence 2022
Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Philip J Mease¹, Qi Wei², Michael Chiorean¹, Lulu Iles-Shih¹, Wanessa Matos², Andrew Baumgartner², Sevda Molani², Yeon Mi Hwang², Basazin Belhu² and Jennifer Hadlock², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Institute for Systems Biology, Seattle, WA
Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…
Abstract Number: 0382 • ACR Convergence 2022
Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
Gregory McDermott¹, Faith Selzer¹, Sizheng Zhao², Joerg Ermann³ and Jeffrey Katz¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Manchester, Liverpool, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) experience significant delay between symptom onset and diagnosis. Determinants of delay are incompletely understood. We investigated the associations between…
Abstract Number: 0417 • ACR Convergence 2022
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
Dafne Capelusnik¹, Diego Benavent², Désirée van der Heijde³, Robert Landewé⁴, Denis Poddubnyy⁵, Astrid van Tubergen⁶, Louise Falzon⁷, Victoria Navarro-Compán⁸ and Sofia Ramiro⁹, ¹Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ²La Paz University Hospital, Madrid, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Maastricht UMC+, Maastricht, Netherlands, ⁷Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁸Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The ASAS-SPEAR (SPondyloarthritis EARly definition) project aims to develop a consensual definition of early SpA. Therefore, it is important to know whether treatment earlier…
Abstract Number: 0857 • ACR Convergence 2022
Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs for Classification in Juvenile Spondyloarthritis
Pamela Weiss¹, Timothy Brandon², Robert G Lambert³, David Biko⁴, Nancy Chauvin⁵, Michael Francavilla⁴, Nele Herregods⁶, Alison Hendry⁷ and Walter P Maksymowych⁸, ¹Children's Hospital of Philadelphia, Glen Mills, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Alberta, Edmonton, AB, Canada, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Penn State Health, Hershey, PA, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Middlemore Hospital, Auckland, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Radiographs are neither sensitive nor reliable in assessment of axial disease in juvenile spondyloarthritis (JSpA). However, they are still performed in some areas due…
Abstract Number: 1044 • ACR Convergence 2022
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
cristina Valero-Martinez¹, Judith Font Urguelles², Meritxell Sallés³, BEATRIZ E. JOVEN⁴, Felipe Julio Ramirez Garcia⁵, Xavier Juanola⁶, Raquel Almodóvar⁷, ana Laiz⁸, Mireia Moreno⁹, Manel Pujol¹⁰, Luis Sala-Icardo¹¹, Santos Castañeda¹² and Rosario Garcia-Vicuña¹, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Althaia Xarxa Assistencial Universitària, Manresa, Spain, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Hospital Clínic, Barcelona, Spain, ⁶Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain, ⁷Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁸Unitat Territorial de Reumatologia Sant Pau-Dos de Maig, Barcelona, Spain, ⁹Hospital Universitari Parc Taulí, Sabadell, Spain, ¹⁰Hospital Universitario MútuaTerrassa, Terrassa, Spain, ¹¹Hospital Universitario de Torrejón de Ardoz, Madrid, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Combined biological or targeted therapy (CBTT) is rarely considered in clinical practice due to contraindication in guidelines, potential safety concerns and high costs. However,…
Abstract Number: 1294 • ACR Convergence 2022
Translation and Cross-cultural Adaptation of the CORS into Spanish
Victoria Navarro-Compán¹, Diego Benavent², Andrea Jochems³, Dora Pascual-Salcedo³, Gijs Jochems⁴, Sofia Ramiro⁵, Wim van Lankveld⁶ and Chamaida Plasencia-Rodriguez⁷, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology Group, Hospital Universitario La Paz, Madrid, Spain, ⁴Promega Biotech Ibérica, Madrid, Spain, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶NA, Amsterdam, Netherlands, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Spain
Background/Purpose: Rheumatic diseases substantially affect the lives of patients, with complex associations between disease severity and self-perceived health status. In this regard, the Coping with…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
Abstract Number: 2254 • ACR Convergence 2022
Detection of Active Inflammatory and Structural Changes Indicative of Axial Spondyloarthritis on MRI of Sacroiliac Joint Using a Deep Learning Framework
Keno Kyrill Bressem¹, Lisa Adams¹, Fabian Proft², Kay-Geert Hermann³, Torsten Diekhoff¹, Laura Spiller¹, Stefan Niehues¹, Marcus Makowski⁴, Bernd Hamm¹, Mikhail Protopopov⁵, valeria Rios-Rodriguez⁶, Hildrun Haibel⁷, Judith Rademacher⁵, Murat Torgutalp⁷, Robert G Lambert⁸, Xenofon Baraliakos⁹, Walter P Maksymowych¹⁰, Janis Vahldiek¹ and Denis Poddubnyy², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Technical University of Munich, Munich, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁷Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ¹⁰Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Magnetic resonance tomography (MRI) plays a key role in the early diagnosis of axial spondyloarthritis (axSpA). However, the detection of changes indicative of axSpA…
Abstract Number: 0384 • ACR Convergence 2022
Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
Jenny Lin Hong Shi¹, Steven H Lam², Ho So³, Edmund Li¹, Tena Li¹, Cheuk Chun Szeto¹ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Faculty of Medicine, CUHK, Hong Kong, Hong Kong
Background/Purpose: In the general population, hypertension (HT) is reported as one of the most important risk and modifiable factors to develop CVD. It is well…
Abstract Number: 0419 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
Walter P Maksymowych¹, Xenofon Baraliakos², Atul Deodhar³, Denis Poddubnyy⁴, Fabiana Ganz⁵, Tianming Gao⁶, Jayne Stigler⁶, Anna K Shmagel⁶, Peter Wung⁶ and Filip Van den bosch⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Oregon Health & Science University, Portland, OR, USA, Portland, OR, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵AbbVie, Inc., Luzern, Switzerland, ⁶AbbVie, Inc., North Chicago, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: The Phase 3 SELECT-AXIS 2 trial (NCT04169373) assessed the efficacy and safety of upadacitinib (UPA) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Here, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].